- Evonik projects their full-year adjusted EBITDA to be at the low end of €2 billion to €2.3 billion.
- For the second quarter, the adjusted EBITDA was €509 million, down 12% compared to the previous year, with an estimate of €519.7 million.
- Advanced Technologies division reported an adjusted EBITDA of €266 million, while Custom Solutions recorded €254 million.
- The adjusted EBITDA margin was 14.5%, slightly below last year’s 14.7%, but above the estimated 14%.
- Total sales amounted to €3.50 billion against an estimated €3.74 billion.
- Revenue for Advanced Technologies came in at €1.51 billion and for Custom Solutions at €1.37 billion.
- Evonik aims for a cash conversion rate of around 40% in 2025.
- Capital expenditures are set to decrease by €100 million, bringing them to approximately €750 million in 2025.
- Return on capital employed is expected to match the previous year’s rate of 7.1%.
- Analyst ratings include 10 buys, 4 holds, and 3 sells.
Evonik Industries on Smartkarma
Analyst coverage of Evonik Industries on Smartkarma showcases a bullish outlook by Baptista Research. In their report titled “Evonik Industries: Initiation of Coverage – Will Methionine Market Tightness Trigger a Massive Upside Surprise?”, the analysts highlight the positive performance of Evonik Industries AG, a global leader in specialty chemicals, during the first quarter of 2025. The company demonstrated a significant year-over-year increase in EBITDA and free cash flow, exceeding the previous year’s figures by over 50%. Despite facing challenges in the macroeconomic environment, Evonik maintained its full-year guidance, driven by strong performances in its Specialty Additives and Nutrition & Care segments.
A look at Evonik Industries Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Evonik Industries AG, a manufacturer of specialty chemicals, has been identified with promising long-term prospects according to Smartkarma’s Smart Scores. With strong scores in Dividend and Value, Evonik Industries stands out for its ability to provide solid returns to investors and its attractive valuation. Additionally, the company showcases decent scores in Growth, Resilience, and Momentum, indicating a stable performance in these key areas as well. These scores collectively suggest a positive outlook for Evonik Industries, making it an intriguing company to watch for potential investment opportunities.
Evonik Industries AG is a leading player in the specialty chemicals sector, offering a diverse range of products including those for consumer goods, animal nutrition, and pharmaceuticals. With an overall favorable evaluation by Smartkarma’s Smart Scores, particularly in Dividend and Value, Evonik Industries demonstrates its strength in delivering shareholder value while maintaining an appealing pricing position. The company’s respectable scores in Growth, Resilience, and Momentum further underscore its position as a robust player in the market. Investors looking for a company with a solid foundation and growth potential may find Evonik Industries a compelling option for their portfolios.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
